Creative Planning Has $8.63 Million Stock Holdings in GSK plc (NYSE:GSK)

Creative Planning raised its holdings in GSK plc (NYSE:GSK) by 3.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 211,100 shares of the pharmaceutical company’s stock after acquiring an additional 7,854 shares during the quarter. Creative Planning’s holdings in GSK were worth $8,630,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. JTC Employer Solutions Trustee Ltd lifted its stake in shares of GSK by 71.3% in the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after buying an additional 8,800,822 shares during the last quarter. Primecap Management Co. CA lifted its stake in shares of GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock worth $558,689,000 after buying an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD lifted its stake in shares of GSK by 37.8% in the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after buying an additional 1,512,442 shares during the last quarter. Acadian Asset Management LLC increased its position in GSK by 180.0% during the first quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock worth $95,129,000 after acquiring an additional 1,426,935 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in GSK during the second quarter worth $52,487,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on GSK shares. Jefferies Financial Group boosted their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Finally, Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, GSK presently has a consensus rating of “Buy” and an average target price of $50.00.

GSK Trading Down 0.4 %

Shares of GSK stock opened at $38.00 on Wednesday. The firm has a market capitalization of $78.75 billion, a PE ratio of 13.77, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The company’s fifty day moving average price is $41.33 and its two-hundred day moving average price is $41.21. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The firm had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. On average, analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were issued a $0.3843 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. This represents a $1.54 annualized dividend and a dividend yield of 4.05%. GSK’s dividend payout ratio is presently 55.80%.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.00% of the stock is owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.